NAVSUNLI Trademark

Trademark Overview


On Monday, September 25, 2023, a trademark application was filed for NAVSUNLI with the United States Patent and Trademark Office. The USPTO has given the NAVSUNLI trademark a serial number of 98196308. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, December 24, 2024. This trademark is owned by REGENXBIO Inc.. The NAVSUNLI trademark is filed in the Pharmaceutical Products category with the following description:

Biological preparations for medical use in the treatment of genetic diseases and disorders, and central nervous system (CNS) disorders, namely, neurodegenerative disorders; pharmaceutical preparations, namely, recombinant adeno-associated viral (rAAV) vectors for use in gene therapy; Pharmaceutical preparations for the treatment of genetic diseases and disorders and central nervous system (CNS) disorders, namely, neurodegenerative disorders; Pharmaceutical preparations for use in gene therapy; Clinical medical reagents for use in gene therapy; Pharmaceutical preparations for the treatment of genetic disorders and neurodegenerative disorders; Therapeutic pharmaceutical compositions that include recombinant adeno-associated viral (rAAV) vectors to provide a platform for specific expression of biologics with therapeutic effect in gene therapy; Pharmaceutical preparations containing adeno-associated viral (AAV) vectors and nucleic acids for a system delivering genes to biological cells for...

General Information


Serial Number98196308
Word MarkNAVSUNLI
Filing DateMonday, September 25, 2023
Status688 - NOTICE OF ALLOWANCE - ISSUED
Status DateTuesday, December 24, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 12, 2024

Trademark Statements


Goods and ServicesBiological preparations for medical use in the treatment of genetic diseases and disorders, and central nervous system (CNS) disorders, namely, neurodegenerative disorders; pharmaceutical preparations, namely, recombinant adeno-associated viral (rAAV) vectors for use in gene therapy; Pharmaceutical preparations for the treatment of genetic diseases and disorders and central nervous system (CNS) disorders, namely, neurodegenerative disorders; Pharmaceutical preparations for use in gene therapy; Clinical medical reagents for use in gene therapy; Pharmaceutical preparations for the treatment of genetic disorders and neurodegenerative disorders; Therapeutic pharmaceutical compositions that include recombinant adeno-associated viral (rAAV) vectors to provide a platform for specific expression of biologics with therapeutic effect in gene therapy; Pharmaceutical preparations containing adeno-associated viral (AAV) vectors and nucleic acids for a system delivering genes to biological cells for use in the treatment of diseases, sicknesses, and disorders, namely, lysosomal storage disorders; gene therapy preparation for medical use containing genetic materials for sustained protein expression, namely, lysosomal enzyme expression

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, October 10, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameREGENXBIO Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressRockville, MD 20850

Party NameREGENXBIO Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressRockville, MD 20850

Trademark Events


Event DateEvent Description
Thursday, September 28, 2023NEW APPLICATION ENTERED
Tuesday, October 10, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, December 8, 2023TEAS VOLUNTARY AMENDMENT RECEIVED
Wednesday, April 10, 2024ASSIGNED TO EXAMINER
Wednesday, April 17, 2024NON-FINAL ACTION WRITTEN
Wednesday, April 17, 2024NON-FINAL ACTION E-MAILED
Wednesday, April 17, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, April 29, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, April 29, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, April 29, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, July 10, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Wednesday, July 10, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Wednesday, July 24, 2024PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Wednesday, July 24, 2024TEAS VOLUNTARY AMENDMENT RECEIVED
Thursday, October 3, 2024EXAMINER'S AMENDMENT ENTERED
Thursday, October 3, 2024EXAMINERS AMENDMENT -WRITTEN
Thursday, October 3, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, October 3, 2024EXAMINERS AMENDMENT E-MAILED
Thursday, October 3, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, October 23, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 12, 2024PUBLISHED FOR OPPOSITION
Tuesday, November 12, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Thursday, December 12, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, December 12, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, December 12, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, December 24, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT